NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 7, 2020--
“After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given NBTXR3’s universal mode of action, our proof-of-concept in soft tissue sarcoma, and promising results from our phase I trial in head and neck cancers, we are confident that NBTXR3 activated by radiation therapy has the potential to significantly improve treatment outcomes for head and neck cancer patients. Beyond head and neck, we will continue to expand into additional indications and combination therapies. Ultimately, we aim to change the oncology treatment paradigm for millions of patients around the world.” – Laurent Levy, CEO of Nanobiotix
NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205 – the ‘’ Company ’’) today announced its global development strategy for 2020 and beyond, following proof-of-concept (POC) and European market approval for NBTXR3 in locally advanced soft tissue sarcoma of the extremities and trunk wall (Brand Name: Hensify®) in 2019. The Company will continue to prioritize its registration pathway in the US and EU for the treatment of head and neck cancers, while also working to advance the Nanobiotix immuno-oncology (I/O) program and evaluate NBTXR3 in other indications such as lung, pancreatic, esophageal, hepatocellular carcinoma (HCC), prostrate, and rectal cancers. To execute this plan, Nanobiotix will focus on H&N cancers while its collaborators (i.e. The University of Texas MD Anderson Cancer Center (MD Anderson) in the US and PharmaEngine in Asia) are working on other indications.
Global Development Plan Visualization
ANTICIPATED NEXT STEPS
Development in Head and Neck Moving Forward
Phase III Registration Trial for NBTXR3 in head and neck patients ineligible for cisplatin
TRIAL NAME: STUDY 312
Design completed based on last interactions with FDA and European payers (EUnetHTA)
Jan 2020 - Submission of final protocol to FDA and other global regulatory bodies
Phase I and Phase I Expansion Trial for NBTXR3 in head and neck patients ineligible for cisplatin or intolerant to cetuximab
TRIAL NAME: Study 102 / 102 Expansion
Phase I dose escalation completed / data reported – 19 patients
Dose Expansion – 38 of 44 patients recruited
Q1 2020 - Update of dose escalation patients follow-up
Mid 2020 - First expansion phase data on efficacy and safety of dose expansion
Phase I/II Trial for NBTXR3 combined with cisplatin for head and neck patients
TRIAL NAME: PEP503-HN-1002
3 rd dose level recruiting
H2 2020- Last patient in for 5 th (last) dose level
Immuno-Oncology Program with NBTXR3
Phase I Basket Trial for NBTXR3 combined with pembrolizumab or nivolumabin H&N, lung metastasis, liver metastasis patients
TRIAL NAME: Study 1100
First patients treated
Protocol extended to include patients with lung and liver metastases from any primary tumor. Recruitment ongoing
Mid-year 2020 - first data reported
Phase II Trial of reirradiation with NBTXR3 combined with anti-PD-1/L1 for inoperable, locally advanced HN cancer
Phase II Trial for NBTXR3 combined with anti-PD-1 or anti-PD-L1 in Stage IV lung cancer
Phase I Trial for NBTXR3 combined with anti- CTLA4 and anti-PD-1 or PD-L1 in patients with advanced solid tumors and lung or liver mets
Phase II Trial for NBTXR3 for recurrent/metastatic HNSCC patients with limited PD-L1 expression
MD Anderson trials
Final stage of protocol development
Q2-Q3 2020 - Submission of protocols to FDA
Development Across Other Indications
Phase I Trial for NBTXR3 in hepatocellular carcinoma and liver metastasis patients
TRIAL NAME: Study 103
Recruitment of the last patient at the 5th (last) dose level (one patient left to be treated)
Q1 2020 - Update on results
Phase I Trial for NBTXR3 in prostate cancer patients
TRIAL NAME: Study 104
2 nd dose level recruiting
Q4 2020 - Update on results
Phase I Trial for NBTXR3 in pancreatic cancer
Phase I Trial for NBTXR3 in lung cancer patients in need of reirradiation
Phase I Trial for NBTXR3 inesophageal cancer patients
MD Anderson trials
Pancreas – Regulatory process ongoing
Lung re-irradiation / Esophageal – Submission of final protocol to regulatory process
Q2 2020 - First patient treated in pancreas
Q3 2020 - Lung re-irradiation / Esophageal first patient treated
Phase I/II Trial for NBTXR3 combined with chemotherapy in rectal cancer patients
TRIAL NAME: PEP503-RC-1001
4 th (last) dose level recruiting
H2 2020 - Report phase I results
Next Steps in Soft Tissue Sarcoma
Phase III Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients
TRIAL NAME: Act.In.Sarc
Trial completed / data reported
H2 2020- Further follow up of the patients
Post-Approval Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients
TRIAL NAME: TBD
Design established (100 patients)
H2 2020 - Trial authorization by the relevant regulatory bodies expected
Development in Head and Neck Moving Forward
There are approximately 700,000 new head and neck cancer patients worldwide each year—300,000 of these patients reside in the US and the European Union (EU) 1. Of these patients at diagnosis, 90% suffer from local disease and the remaining 10% have metastatic disease. 70-80% of all Head and Neck patients will receive radiation therapy, but significant unmet medical needs remain regarding either local control, systemic control, toxicity, or some combination of the three 2. This is especially challenging for patients ineligible for platinum-based chemotherapy (cisplatin).
Global Registration Trial for NBTXR3 in Head and Neck Patients Ineligible for Cisplatin
As previously announced, Nanobiotix has begun interacting with the US Food and Drug Administration (FDA) on its regulatory pathway and met with the agency in October 2019 to refine the design elements of Study 312—a phase III investigator’s choice, dual-arm, randomized (1:1) global registration trial including elderly head and neck cancer patients who are ineligible for platinum-based chemotherapy (cisplatin).
More than half of head and neck cancers include large primary tumors which may invade underlying structures and/or spread to regional nodes. Treatment of these locally advanced forms of the disease ordinarily requires aggressive, concerted measures. Due to potential comorbidities and toxicities associated with treatment, elderly and frail patients suffer from limited therapeutic options. Study 312 aims to target the unmet needs of this population.
Patients in the control arm will receive radiation therapy with or without cetuximab (investigator’s choice), and patients in the treatment arm will receive NBTXR3 activated by radiation therapy with or without cetuximab (investigator’s choice). The trial will recruit around 500 patients, the initial readout will be based on event-driven progression-free survival (PFS), and the final readout will be based on PFS and overall survival (OS). The study will be powered to demonstrate the OS superiority of NBTXR3 activated by radiation therapy. In addition, quality of life (QoL) will be measured as a key secondary outcome.
The Company’s next step is to submit the final trial design to FDA and other global regulatory bodies within the month. A futility analysis is expected 18 months after the first patient is randomized, the interim analysis for PFS superiority is expected at 24-30 months, and final analysis will report on PFS and OS. In the event of favorable data from the initial readout, Nanobiotix plans to apply for conditional registration in the US.
Confirming Efficacy with Phase I (Study 102) Expansion
Nanobiotix has already reported promising early signs of efficacy for patients with head and neck cancer through Study 1023 —a phase I trial of NBTXR3 nanoparticles activated by intensity-modulated radiation therapy (IMRT) in the treatment of advanced-stage head and neck squamous cell carcinoma (HNSCC). The patient population for Study 102 includes elderly and frail patients who are ineligible for cisplatin or intolerant to cetuximab.
As a result of this report, the Company launched an expansion cohort with 44 additional patients to strengthen preliminary efficacy data. Recruitment for the expansion cohort has reached 38 of 44 patients and the initial readout is expected by mid-2020. Depending on the favorability of the final expansion phase data, the Company may seek to expedite the regulatory process in the EU.
Additional Development in Head and Neck with Collaborators
To serve as many head and neck cancer patients as possible and as mentioned above, the Company has engaged in ongoing clinical collaborations with MD Anderson in the US and PharmaEngine in Asia.
The Company is collaborating with MD Anderson on nine (9) clinical trials across multiple indications, three (3) of which are expected to evaluate head and neck cancer in patient populations outside of the trials Nanobiotix is executing alone (e.g. borderline resectable, inoperable and neck cancer (re-irradiation), etc.)
The head and neck portion of the PharmaEngine collaboration features a phase I/II trial designed to evaluate the safety and feasibility of NBTXR3 activated by radiation therapy in combination with cisplatin for patients with locally advanced cancer of the oral cavity and oropharynx.
Immuno-Oncology Program with NBTXR3
In addition to the main program evaluating the use of NBTXR3 as a single agent, and as mentioned above, Nanobiotix is running a global I/O program. For the past decade, there has been excitement around the ability of I/O agents (immune checkpoint inhibitors or ICIs) to activate the immune system to attack tumor cells. However, many tumors exhibit little or no response to these therapies and are considered “cold,” due to a lack of immunogenicity. As a result, a small fraction of patients realize the benefits of ICIs 4.
The Nanobiotix I/O program is comprised of Study 1100 —an I/O basket trial in the US—a pre-clinical collaboration with MD Anderson, and a large-scale clinical collaboration with MD Anderson including several trials,. The program aims to evaluate the potential for NBTXR3 activated by radiation therapy in combination with immune checkpoint inhibitors to convert checkpoint inhibitor non-responders into responders; provide better local and systemic control; and increase survival.
Study 1100 evaluates NBTXR3 in combination with anti-PD-1, includes three cohorts, is recruiting and has four activated sites. The head and neck cohort includes patients with locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). The remaining cohorts include patients with lung and liver metastasis. While cohorts two and three initially called for liver and lung metastasis patients with HNSCC or non-small cell lung cancer (NSCLC) as the primary tumor, the protocol was recently expanded to include patients with lung and liver metastases from any primary cancer eligible for anti-PD-1 therapy (e.g. metastatic melanoma, metastatic NSCLC, metastatic small cell lung cancer, metastatic HNSCC, metastatic cervical cancer, metastatic urothelial cancer, metastatic gastric cancer, metastatic Merkel cell carcinoma, and metastatic microsatellite-high or mismatch repair deficient cancers, etc.).
The I/O portion of the Nanobiotix clinical collaboration with MD Anderson plans to evaluate NBTXR3 activated by radiation therapy in combination with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, and anti-CTLA-4) in patients with locally advanced and metastatic lung cancer.
Development Across Other Indications
Study 103 —evaluating NBTXR3 activated by radiation therapy for the treatment of patients with HCC and liver metastasis—is recruiting the last patient at the 5 th (last) dose level and final results are expected in the first quarter of this year.
Furthermore, the Company is evaluating NBTXR3 activated by radiation therapy for patients with prostate cancer through Study 104; for patients with naïve esophageal cancer, and pancreatic cancer through the clinical collaboration with MD Anderson; and in combination with chemotherapy for patients with rectal cancers through the PharmaEngine collaboration. Two additional trials with MD Anderson are under discussion.
Next Steps in Soft Tissue Sarcoma
Given positive phase III results and market approval for NBTXR3 in Europe for the treatment of soft tissue sarcoma of the extremities and trunk wall, the Company is currently preparing a post-registrational trial that will continue evaluating safety and efficacy, and will provide patients with access to the product. Around 100 patients should be recruited for this trial, which is expected to launch in the second half of 2020.
NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide standards of radiation care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorité des Marchés Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on www.nanobiotix.com ) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
1 Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
2 Delaney, G., Jacob, S., Featherstone, C., & Barton, M. (2005). The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence‐based clinical guidelines. Cancer: Interdisciplinary International Journal of the American Cancer Society, 104(6), 1129-1137.
3 See Company’s press release dated September 20, 2019.
4 Spigel, David R., et al. (2015): 8009-8009. ; Ferris, Robert L., et al. New England Journal of Medicine 375.19 (2016): 1856-1867. ; Borghaei, Hossein, et al. New England Journal of Medicine 373.17 (2015): 1627-1639. ; Garon, Edward B., et al. New England Journal of Medicine 372.21 (2015): 2018-2028. ; Seiwert, Tanguy Y., et al. The lancet oncology 17.7 (2016): 956-965. ; Antonia, Scott J., et al. New England Journal of Medicine 377.20 (2017): 1919-1929.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200107005982/en/
+1 (617) 852-4835
Senior Manager, Corporate Marketing
+33 (0) 1 70 61 00 18
email@example.comInvestor Relations Department
Noel Kurdi (US)
Director, Investor Relations
+1 (646) 241-4400
firstname.lastname@example.orgRicky Bhajun (EU)
Senior Manager, Investor Relations
+33 (0)1 79 97 29 99
France –TBWA Corporate
+ 33 (0) 437 47 36 42
+1 (212) 223-4017
KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE MASSACHUSETTS
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY CLINICAL TRIALS
Copyright Business Wire 2020.
PUB: 01/07/2020 02:04 PM/DISC: 01/07/2020 02:04 PM